Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Marco Ruella, MD

Marco Ruella, MD Physician

Scientific Director of the Lymphoma Program Assistant Professor of Pathology and Laboratory Medicine Assistant Professor of Medicine

Languages spoken:

  • Italian

Dr. Ruella is employed by Penn Medicine.

No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Hematology

Programs & Centers:

Clinical Expertise:

  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Acute Promyelocytic Leukemia
  • Adult T-Cell Leukemia
  • Adult T-Cell Lymphoma
  • AIDS Related Malignancies
  • Amyloidosis
  • Anaplastic Large Cell Lymphoma
  • Blood Cancer
  • Bone Marrow Biopsy
  • Bone Marrow Failure Syndromes
  • Burkitt Lymphoma
  • Cancer During Pregnancy
  • Castleman Disease
  • Chronic Lymphocytic Leukemia
  • Chronic Myelocytic Leukemia
  • Chronic Myelomonocytic Leukemia
  • CNS Lymphoma
  • Cutaneous Lymphoma
  • Eosinophilic Granuloma
  • Erdheim-Chester Disease
  • Essential Thrombocytosis
  • Graft Versus Host Disease
  • Hairy Cell Leukemia
  • Hematologic Malignancies
  • Histiocytosis
  • HIV Lymphoma
  • HIV Malignancies
  • Hodgkin Lymphoma
  • Intraocular Lymphoma
  • Large Granular Lymphocytic Leukemia
  • Leukemia
  • Light Chain Disorders
  • Marginal Zone Lymphoma
  • Mediastinal Lymphoma
  • Monoclonal Gammopathy of Undetermined Significance
  • Mucosa-Associated Lymphoid Tissue Lymphoma
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Non-Hodgkin Lymphoma
  • Pelvic Malignancy During Pregnancy
  • Peripheral T-Cell Lymphoma
  • Plasma Cell Dyscrasia
  • POEMS Syndrome
  • Polycythemia
  • Primary Myelofibrosis
  • Prolymphocytic Leukemia
  • Refractory Anemia With Excess Blasts
  • Sezary Syndrome
  • Transformed Lymphoma
  • Waldenstrom Macroglobulinemia (WM)
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • OPR Medicare
  • OPR New Jersey Medicaid
  • OPR Pennsylvania Medicaid

Education and Training

Medical School:
Fellowship:

Memberships

AbClon Inc., International American Association for Cancer Research, International American Society of Hematology (and Scientific Committee on Transplantation Biology and Cellular Therapies, 2019-2022), International Early-Career Scientist Committee, Society for Immunotherapy of Cancer (SITC), International European Hematology Association, International International Society of Cell Therapy, International Italian Lymphoma Foundation, International NanoString Technologies, International Society for Immunotherapy of Cancer, International

Hospital Affiliation

Dr. Ruella is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.

Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally designing combined innovative immunotherapies for relapsing/refractory leukemia and lymphoma. He is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CAR T therapy. His work has been recognized through numerous awards including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), and most recently the 2018 American Society of Hematology Joanne Levy, MD, Memorial Award for Outstanding Achievement. Dr. Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. After completing his fellowship, he was an attending physician in the Hematology and Cell Therapy Division of the Mauriziano Hospital and an Instructor at the Biotechnology School at the University of Torino. From 2012, he was a postdoctoral fellow, and then an instructor at the University of Pennsylvania in the Center for Cellular Immunotherapies where he worked with Drs. June and Gill until appointment to his current position in 2018.


Selected Publications:

Marco Ruella, David M Barrett, Olga Shestova, Jessica Perazzelli, Avery D Posey, Jr., Seok Jae Hong, Miroslaw Kozlowski, Simon F Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill: A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells Blood : 2019.

1., Singh, Nathan, MD, Frey, Noelle V., Engels, Boris, PhD, Barret, David M., Shestova, Olga, PhD, Ravikumar, Pranali, MS, Shyu, Amy, Highfill, Steven PhD, Zhao, Linlin, Peng, Liaomin, Granda, Brian, Ramones, Melissa, Lu, Xueqing Maggie, Christian, David A, PhD, Perazzelli, Jessica, Lacey, Simon F., PhD, Roy, Nathan, Burkhardt, Janis K., PhD, Colomb, Florent, Abdel-Mohsen, Mohamed, Young, Regina M., PhD, Brogdon, Jennifer, PhD, Grupp, Stephan, MD, PhD, June, Carl H, MD Maude, Shannon L., MD, PhD, Gill, MD: Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy American Society of Hematology Annual Meeting Orlando, Florida (247): 2019.

Svoboda, Jakub, MD, Ballard, Hatcher J., BS, Chong, Elise A., MD, LaRose, Meredith I, MD, Bair, Steven M., MD, Namoglu, Esin C., B.S., Hughes, Mitchell E., PharmD, Nasta, Sunita Dwivedy, MD, Landsburg, Daniel J., MD, Barta, Stefan K., MD, MRCP, MS, Gerson, James N., MD, Weber, Elizabeth, BSN, RN, Walling, Chase BS, Ruella, Marco, MD, Frey, Noelle V., MD, Porter, David L., MD and Schuster, Stephen J., MD: Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas American Society of Hematology Annual Meeting Orlando, Florida (1606): 2019.

Nasta, Sunita Dwivedy, MD, Hughes, Mitchell E. PharmD, Namoglu, Esin C. B.S., Landsburgh, Daniel J., MD, Chong, Elise A., MD, Barta, Stefan K. MD, MRCP, MS, Frey, Noelle V., MD, Gerson, James N., MD, Maity, Amit, MD, PhD, Plastaras, John, MD, Porter, David L., MD, Ruella, Marco, MD, Svoboda, Jakub, MD, Ballard, Hatcher J., BS and Schuster, Stephen J., MD: A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy American Society of Hematology Annual Meeting Orlando, Florida (4108): 2019.

Marco Ruella, Carl H. June: Beat Pediatric ALL MRD: CD28 CAR-T and Transplant Blood : 2019.

Nasta, Sunita Dwivedy, MD, Namoglu, Esin C., B.S., Hughes, Mitchell E., PharmD, Chong, Elise A., MD, Svoboda, Jakub, MD, Ballard, Hatcher J., BS, Landsburg, Daniel J., MD, LaRose, Meredith I, MD, Barta, Stefan K., MD, MRCP, MS, Gerson, James N., MD, Ruella, Marco, MD, Frey, Noelle V., MD, Schuster, Stephen J., MD and Porter, David L., MD: Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience American Society of Hematology Annual Meeting Orlando, Florida (3240): 2019.

Wang, Meng, BS, Pruteanu, Iulian, PhD, Cohen, Adam D., MD, Garfall, Alfred L, MD, Milone, Michael C., Tian, Lifeng, PhD, Gonzalez, Vanessa E., Gill, Saar, MD, MRCP, FRCPath, Frey, Noelle V., MD, Barrett, David M., Ruella, Marco, MD, Lacey, Simon F, PhD, Svoboda, Jakub MD, Chong, Elise A. MD, Fraietta, Joseph A, PhD, Davis, Megan, PhD, Nasta, Sunita D, MD, Levine, Bruce L, PhD, Siegel, Don L., MD, PhD, Maude, Shannon L., MD, PhD, Schuster, Stephen J., MD, Stadtmauer, Edward A., MD, FACP, Grupp, Stephan, MD: Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors American Society of Hematology Annual Meeting Orlando, Florida (622): 2019.

Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M.: Novel Immunotherapies for T Cell Lymphoma and Leukemia Curr Hematol Malig Rep. : 2018.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24(10):1499-1503 : 2018.

Ascierto Paolo A, Brugarolas James, Buonaguro Luigi, Butterfield Lisa H, Carbone David, Daniele Bruno, Ferris Robert, Fox Bernard A, Galon Jérôme, Gridelli Cesare, Kaufman Howard L, Klebanoff Christopher A, Melero Ignacio, Nathan Paul, Paulos Chrystal M, Ruella Marco, Sullivan Ryan, Zarour Hassane, Puzanov Igor: Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). Journal for immunotherapy of cancer 6 (1): 69,2018.

View all publications

Academic Contact Info

South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd

Philadelphia, PA 191004
Phone: (215) 746-4880
Patient appointments: 800-789-7366 (PENN)